Risk for Myopericarditis Minimal Following COVID-19 Vaccination
A study was conducted to determine the incidence of myopericarditis following COVID-19 vaccination compared with non-COVID-19 vaccination.
A study was conducted to determine the incidence of myopericarditis following COVID-19 vaccination compared with non-COVID-19 vaccination.
Two 50-µg doses of the mRNA-1273 vaccine are safe and effective for children aged 6 to 11 years.
Evidence of quality control problems was hidden by a company contracted by the US government to produce hundreds of millions of COVID-19 vaccine doses, a new House committee report shows.
During omicron predominance, the estimated vaccine effectiveness (VE) of the BNT162b2 two-dose vaccination among children and adolescents was modest and decreased rapidly.
Graham M. Snyder, MD, MS, provides further insight into a study that evaluated the effects of an early return-to-work program that reduced the quarantine period for clinicians who remained asymptomatic after exposure to COVID-19.
Citing the accumulated data on a raised risk for thrombosis with thrombocytopenia syndrome (TTS), the US Food and Drug Administration greatly restricted the recommended use of the Johnson & Johnson COVID-19 vaccine.
Coronavirus-like particles (CoVLP), which are produced in plants, combined with an adjuvant (Adjuvant System 03 [AS03]) forms a candidate vaccine that is effective for preventing COVID-19.
Only 18% of parents of children younger than 5 years say they plan to get their child vaccinated against COVID-19 as soon as they can, while nearly four in 10 say they will “wait and see” before getting shots for their child.
Adult vaccination rates and socioeconomic factors impacted children’s mental health during the first year of the COVID-19 pandemic.
Moderna announced that it has asked the US Food and Drug Administration to authorize the emergency use of its COVID-19 vaccine for children younger than 6 years old.